Showing 761 - 780 results of 10,368 for search '"database"', query time: 0.09s Refine Results
  1. 761

    Impact of Oseltamivir and Diabetes Development by Bor-Show Tzang, Chih-Chen Tzang, Pei-Hua Chuang, I-Ying Kuo, Yu-Chun Pan, Pei-Hsun Wu, Tsai-Ching Hsu

    Published 2025-01-01
    Subjects: “…Taiwan National Health Insurance Research Database…”
    Get full text
    Article
  2. 762
  3. 763
  4. 764
  5. 765

    Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database by A. Visram, A. De La Torre, D. White, J. Su, E. Masih-Khan, M. Chu, V. Jimenez-Zepeda, A. McCurdy, R. LeBlanc, K. Song, H. Mian, M. Louzada, M. Sebag, D. Bergstrom, J. Stakiw, A. Reiman, R. Kotb, M. Aslam, C. Venner, R. Kaedbey, E. Gul, D. Reece

    Published 2023-12-01
    “…This multi-center retrospective cohort study used the Canadian Myeloma Research Group Database to describe real-world outcomes of patients withanti-CD38 monoclonal antibody (mAb) refractory MM subsequently treated with standard of care (SoC) regimens. …”
    Get full text
    Article
  6. 766

    Not Like Everybody Else. Essays in Honor of Kees Mandemakers by Jan Kok, Hilde Bras, Richard L. Zijdeman

    Published 2021-03-01
    Subjects: “…Historical databases…”
    Get full text
    Article
  7. 767
  8. 768
  9. 769
  10. 770
  11. 771

    Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus (LEGEND-T2DM): a protocol for a series of multinational, real-world comparative cardiovascular effectiveness and safety studies by Rohan Khera, Yuan Lu, Harlan M Krumholz, Martijn J Schuemie, Ruijun Chen, George Hripcsak, Marc A Suchard, Patrick B Ryan, Anna Ostropolets

    Published 2022-06-01
    “…Introduction Therapeutic options for type 2 diabetes mellitus (T2DM) have expanded over the last decade with the emergence of cardioprotective novel agents, but without such data for older drugs, leaving a critical gap in our understanding of the relative effects of T2DM agents on cardiovascular risk.Methods and analysis The large-scale evidence generations across a network of databases for T2DM (LEGEND-T2DM) initiative is a series of systematic, large-scale, multinational, real-world comparative cardiovascular effectiveness and safety studies of all four major second-line anti-hyperglycaemic agents, including sodium–glucose co-transporter-2 inhibitor, glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas. …”
    Get full text
    Article
  12. 772
  13. 773
  14. 774
  15. 775
  16. 776
  17. 777
  18. 778
  19. 779
  20. 780